Citation Tools

Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years

Download to a citation manager

Cite this article as:
Winthrop KL, Tanaka Y, Takeuchi T, et al
Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years